Cartesian Therapeutics opened lower at $6.82, compared with its previous close of $6.88. In the last trading session, the stock traded between $6.11 and $6.82. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Cartesian Therapeutics is now worth
$ 39.65
Resulting in a loss of
$ 60.35 (60.35%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.52 (-7.50%)
Day High
$6.82
Day Low
$6.11
Day Open
$6.82
Prev Close
$6.88
Volume
2,49,345
1W Return
-6.81%
1M Return
-8.98%
3M Return
-25.97%
6M Return
-25.39%
1Y Return
-12.82%
Market Cap ($ Mn)
194
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-40.06%
EPS (TTM)
$-0.38
1 Week
-6.81%
1 Month
-8.98%
3 Months
-25.97%
6 Months
-25.39%
9 Months
-0.56%
Cartesian Therapeutics grants options for 121,900 shares to new hires
Cartesian Therapeutics granted options for 121,900 shares to four new employees. Exercise price set at $7.22, equal to the closing price on October 1, 2026. Options vest 25% after one year, with remaining balance over 36 months. Awards issued under the 2018 Employment Inducement Incentive Award Plan.
1mo agoCartesian Therapeutics reports 6.6-point MG-ADL improvement with Descartes-08 retreatment
Descartes-08 showed a mean MG-ADL reduction of 6.6 points at Month 12 post-retreatment. Median time to retreatment was 16.6 months after initial treatment course. No new safety signals were reported in the five-patient case series. Phase 3 AURORA trial topline data expected in 1Q27.
1mo ago77% of neurologists see CAR T therapy redefining neuro-immune care
77% of surveyed neurologists believe CAR T therapies could redefine neuro-immune disease management. 74% cite safety profiles as a major barrier to widespread adoption. Cartesian Therapeutics’ Descartes-08 has highest physician familiarity among pipeline options. Kyverna’s miv-cel sees 37% extreme interest among surveyed specialists.
2mo agoWedbush reiterates Outperform on Cartesian Therapeutics, keeps $38 target
Wedbush analyst Martin Fan reaffirms an Outperform rating for Cartesian Therapeutics (NASDAQ: RNAC) with a steady $38 price target. The move underscores sustained institutional confidence in the company without adjusting valuation expectations.
2mo agoCartesian Therapeutics grants inducement awards to eight new employees
Cartesian Therapeutics granted inducement awards to eight new employees, consisting of options to purchase 238,700 shares at $10.18 per share. The options vest over four years, starting July 1, 2027, and fully vest by July 1, 2030, with a ten-year term.
4mo agoCartesian Therapeutics grants inducement award to new employee
Cartesian Therapeutics granted an inducement award to a new employee, consisting of an option to purchase 6,100 shares at $5.86 per share. The option vests over four years, with full vesting by June 8, 2030, and was approved by the board under Nasdaq Listing Rule 5635(c)(4).
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in Cartesian Therapeutics is now worth
$ 39.65
Resulting in a loss of
$ 60.35 (60.35%)
Note: Past profits do not guarantee future returns.
